No description available.

The prevailing view is that enhancement of dopamine (DA) transmission in the mesolimbic system consisting of DA neurons in the ventral tegmental area (VTA) that project to the nucleus accumbens (NAc) underlies the rewarding properties of ethanol (EtOH) and nicotine (NIC). Although the dogma is that EtOH enhancement of DA neural activity contributes to enhancement of DA transmission, DA neurons are not sensitive to rewarding levels of EtOH. However, VTA GABA neurons are sensitive to low-dose EtOH. We have shown previously that EtOH modulation of DA release in the NAc is mediated by α6-containing nicotinic receptors (α6*-nAChRs), that α6*-nAChRs mediate low-dose EtOH effects on VTA GABA neurons and EtOH preference, and α6*-nAChRs may be a molecular target for low-dose EtOH. Thus, the most sensitive target for reward-relevant EtOH modulation of mesolimbic DA transmission and the involvement of α6*-nAChRs in the mesolimbic DA reward system remains to be elucidated. The aim of this study was to evaluate EtOH effects on VTA GABAergic input to CINs and DA release in the NAc. Using DIO channel rhodopsin-2 (ChR2) viral injections into the VTA of VGAT Cre mice, we found that VTA GABA neurons send an inhibitory projection to CINs, replicating what has been demonstrated by others. This study investigated the acute and chronic effects of EtOH at this synapse. We demonstrate that EtOH markedly enhances CIN firing rate and that these effects are blocked by the α6-conotoxin MII (α-Ctx MII), knockout of accumbal α6*-nAChRs with α6-shRNA, and atypical GABA receptor antagonists. This study also investigated plasticity at this synapse. We demonstrate that a low frequency stimulation (LFS; 1 Hz, 240 pulses) causes inhibitory long-term depression at this synapse (CIN-iLTD) which is also blocked by α-Ctx MII, α6-shRNA, and atypical GABA receptor antagonists. We also show that CIN-iLTD is blocked in EtOH-dependent mice. Taken together, these findings suggest that EtOH affects the VTA GABAergic projection to CINs via α6*-nAChRs and that atypical GABA receptors also play a role.

Trimethyltin (TMT) destroys specific subfields of the hippocampus in the rat. TMT also increases choline acetyltransferase (ChAT) activity in CA1 of Ammon's horn and the outer molecular layer of the dentate gyrus. This observation suggests that axonal sprouting occurs in the cholinergic septohippocampal system in response to TMT. However, neither does-response nor time course data are available for the effects of TMT on this enzyme. The effects of three dose levels of TMT on ChAT activity in CA1 and the dentate gyrus were determined in Experiment 1 and ChAT activity in these two areas was measured at six time points following exposure to TMT in Experiment 2. Only the highest dose of TMT (6 mg/kg) significantly increased ChAT activity. ChAT activity in the dentate gyrus increased significantly by 3 d after administration and continued to increase until 21 d after exposure. A significant increase was not observed in CA1 until 7 d after exposure to TMT. Asymptotic levels were still reached at d 21. These results indicate a steep dose-response curve for TMT-induced changes in ChAT activity in the hippocampal formation and that this marker of cholinergic activity is more sensitive to perturbation by TMT in the dentate gyrus than Ammon's horn.

Half of the cholinergic neurons of human and primate intrinsic cardiac ganglia (ICG) have a dual cholinergic/noradrenergic phenotype. Likewise, a large subpopulation of cholinergic neurons of the mouse heart expresses enzymes needed for synthesis of norepinephrine (NE), but they lack the vesicular monoamine transporter type 2 (VMAT2) required for catecholamine storage. In the present study, we determined the full scope of noradrenergic properties (i.e. synthetic enzymes and transporters) expressed by cholinergic neurons of mouse ICG, estimated the relative abundance of neurons expressing different elements of the noradrenergic phenotype, and evaluated the colocalization of cholinergic and noradrenergic markers in atrial nerve fibers. Stellate ganglia were used as a positive control for noradrenergic markers. Using fluorescence immunohistochemistry and confocal microscopy, we found that about 30% of cholinergic cell bodies contained tyrosine hydroxylase (TH), including the activated form that is phosphorylated at Ser-40 (pSer40 TH). Dopamine β-hydroxylase (DBH) and norepinephrine transporter (NET) were present in all cholinergic somata, indicating a wider capability for dopamine metabolism and catecholamine uptake. Yet, cholinergic somata lacked VMAT2, precluding the potential for NE storage and vesicular release. In contrast to cholinergic somata, cardiac nerve fibers rarely showed colocalization of cholinergic and noradrenergic markers. Instead, these labels were closely apposed but clearly distinct from each other. Since cholinergic somata expressed several noradrenergic proteins, we questioned whether these neurons might also contain trophic factor receptors typical of noradrenergic neurons. Indeed, we found that all cholinergic cell bodies of mouse ICG, like noradrenergic cell bodies of the stellate ganglia, contained both tropomyosin-related kinase A (TrkA) and p75 neurotrophin receptors. Collectively, these findings demonstrate that mouse intrinsic cardiac neurons (ICNs), like those of humans, have a complex neurochemical phenotype that goes beyond the classical view of cardiac parasympathetic neurons. They also suggest that neurotrophins and local NE synthesis might have important effects on neurons of the mouse ICG.

Dopamine is an important neurotransmitter in the brain, where it plays a regulatory role in the coordination of movement and cognition by acting through two classes of G protein-coupled receptors to modulate synaptic activity. In addition, it has been shown these two receptor classes can exhibit synergistic or antagonistic effects on neurotransmission. However, while the pharmacology of the mammalian dopamine receptors have been characterized in some detail, less is known about the molecular pathways that act downstream of the receptors. As in mammals, the soil nematode Caenorhabditis elegans uses two classes of dopamine receptors to control neural activity and thus can serve as a genetic tool to identify the molecular mechanisms through which dopamine receptors exert their effects on neurotransmission. To identify novel components of mammalian dopamine signaling pathways, we conducted a genetic screen for C. elegans mutants defective in exogenous dopamine response. We screened 31,000 mutagenized haploid genomes and recovered seven mutants. Five of these mutants were in previously-identified dopamine signaling genes, including those encoding the Ga proteins GOA-1 (ortholog of human Gao) and EGL-30 (ortholog of human Gaq), the diacylglycerol kinase DGK-1 (ortholog of human DGK0), and the dopamine receptor DOP-3 (ortholog of human D2-like receptor). In addition to these known components, we identified mutations in the glutamate-gated cation channel subunit GLR-1 (ortholog of human AMPA receptor subunits) and the class A acetycholinesterase ACE-1 (ortholog of human acetylcholinesterase). Behavioral analysis of these mutants demonstrates that dopamine signaling controls acetylcholine release by modulating the excitability of the cholinergic motor neurons in C. elegans through two antagonistic dopamine receptor signaling pathways, and that this antagonism occurs within a single cell. In addition, a mutation in the putative Rab GTPase activating protein TBC-4 was identified, which may suggest a role for this Rab GAP in synaptic vesicle trafficking. Subsequent behavioral and genetic analyses of mutants in synaptic vesicular trafficking components implicate RAB-3-mediated vesicular trafficking in DOP-3 receptor signaling. These results together suggest a possible mechanism for the regulation of dopamine receptor signaling by vesicular trafficking components in the cholinergic motor neurons of C. elegans.

No description available.

Purpose: Inflammation is characterized by complex interactions between pro- and anti- inflammatory cytokines. Recent research has probed the role of the nervous system in inflammation, part of which includes the cholinergic anti-inflammatory pathway that regulates immunologically-mediated inflammation. In this pathway, norepinephrine release from the splenic nerves binds to beta-2-adrenergic receptors on T cells, causing release of acetylcholine (ACh). ACh subsequently suppresses macrophage production and release of pro-inflammatory cytokines. The purpose of this project is to quantify ACh release from isolated murine splenocytes when challenged with different mediators that stimulate T cells in this pathway. Methods:Our method utilizes liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) for quantification of ACh and choline (Ch) in cell culture media. The developed LC-MS/MS method utilizes an isocratic separation (14% 10mM ammonium formate, pH 3, and 86% acetonitrile) on an Atlantis HILIC column (2.1 x 100 mm, 3 micron). The MS operates in positive electrospray (+ESI) mode, monitoring ions specific for ACh, Ch, and their corresponding deuterium labeled internal standards. The calibration range for ACh was 0.01 - 5 micrograms/ml (0.068 - 34 mM) and 10 - 50 micrograms/ml (96 - 480 mM) for Ch. Cell culture media contained neostigmine (0.5 mM) to inhibit cholinesterase. Cell culture media samples are prepared by freeze drying, reconstituting in acetonitrile, and filtering (0.2micron). Potential loss of ACh through degradation during cell culture was evaluated by monitoring d4-labeled ACh with and without the presence of splenocytes for 4 and 24 hours. Splenocytes were challenged with saline (control) or 1 mM (-) isoproterenol for 4 and 24 hours in the next set of experiments, and ACh in the medium was quantified. We also evaluated separate and combined effects of isoproterenol and activation of T cells with CD3 and CD28 antibodies on ACh release. Results:Correlation coefficients (R2) indicate linearity for ACh and Ch in culture media in the calibration range. During the six-min separation, ACh elutes at 3.8 min and Ch at 5.1 min. Deuterium-labeled ACh, when incubated in cell culture media for 4 and 24 hours, with and without splenocytes, showed a small but statistically significant loss of ACh after 24 h compared to 0 time media controls. However, the average loss of ACh was less than 10% and was not affected by the presence of splenocytes, suggesting that it was due to chemical hydrolysis. Incubation for 4 hr with and without splenocytes did not affect recovery of ACh. Treatment of splenocytes with isoproterenol for 4 hours did not cause significant release of ACh. However, significant release of ACh was detected after 24 hours exposure to isoproterenol or T cell activation. Media from untreated splenocytes had an ACh concentration of 0.14 +/- 0.07 mcg/mL. Isoproterenol treated had 0.28 +/- 0.14 mcg/mL, T-cell activated had 0.32 +/- 0.17 mg/mL, and isoproterenol + T-cell activation had 0.47 +/- 0.16 mcg/mL. Using a 1-way analysis of variance, statistically significant differences were detected between each of these groups. Conclusion: The developed LC-MS/MS assay for quantification of ACh and Ch in cell culture media can be applied to the investigation of the cholinergic anti-inflammatory pathway in isolated splenocytes. Statistically significant differences in ACh release between control splenocytes and those treated with isoproterenol and T-cell activation can be detected. Quantitative investigation of this pathway helps provide an improved understanding of ACh dynamics as a mediator released from leukocytes. Further studies using this model and methodology will provide novel insights into cholinergic anti-inflammatory mechanisms and other immunomodulatory actions of non-neuronal ACh.

Single-cell real-time quantitative RT-PCR was used to characterize the mRNA expression of rat neuronal nicotinic acetylcholine receptor (nAChR) subunits α3 and β2 in CA1 hippocampus stratum radiatum and stratum oriens interneurons. α3β2 co-expression was detected in 43% of interneurons analyzed. The nAChR subtype α3β2 was transiently expressed in cells derived from the human embryonic kidney cell line 293 at mRNA levels found in the CA1. The functional properties of α3β2 in HEK-293 cells were characterized by whole-cell patch clamping using acetylcholine (ACh) as an agonist. The kinetics of α3β2 channels were further analyzed by altering the level of α3 DNA transfected into HEK-293 cells. Varying the α3 concentration by more than 100,000 fold did not significantly alter the majority of the kinetics; the 10%-90% rise-time was the main characteristic found to be significantly different. A decrease in α3 concentration illustrated a significant increase in rise time. This and future studies will further our understanding of the extensive role neuronal nAChRs play in modulating hippocampal activity and consequently influencing cognition and memory.

Neuronal nicotinic acetylcholine receptors (nAChRs) are expressed in both the periperhal and central nervous systems, and are involved in pre-, post-, and non-synaptic control of neuronal activation. In the brain, these receptors play an important role in a variety of physiological processes such as cognition, development, learning, and memory formation. Malfunction of these receptors have been implicated in neurodegenerative diseases like Alzheimer's disease (AD), schizophrenia, and Parkinson's disease. To date, 17 different nAChR subunits, including α2-α7 and β2-β4, have been cloned that can form homo- and/or hetero-pentameric ionotropic receptors. The unique combinations of subunit pentamers manifest in distinct functional receptors. Using single-cell real-time quantitative RT-PCR, we identified the individual expression rates and co-expression rates of the different nAChR subunits in rat CA1 hippocampal interneurons in efforts to characterize functional receptors involved in learning and memory. The two-way combination of subunits with highest expression in hippocampal interneurons was α3β2. Moreover, this combination was expressed in ratios near 1:3 or 3:1 α3 to β2 respectively. To investigate the functionality of α3β2 receptors in different stoichiometries, we injected human α3 and rat β2 subunit mRNA in 1:3, 1:1, and 3:1 ratios into Xenopus laevis oocytes for expression. Two-electrode voltage clamp was then performed with the application of different concentrations of ACh to produce full dose-response curves and channel kinetics data. Distinct α3β2 functional channels were identified from the different expression ratios based on significant differences in channel kinetics (i.e.- peak current rise times, peak current decay times, steady state current in forced desensitization) Dose-response curves produced no significant difference in EC50 values in the different expression groups. However, there was a trend to greater agonist sensitivity with increased α3 expression relative to β2. α3β2 receptors were further characterized through forced desensitization of the receptors and generation of IV plots. The findings from this study elucidate the neuronal nAChR subunit combinations that form functional channels in hippocampal interneurons.

The exact mechanism and progression of Alzheimer's disease (AD) at present is not fully understood. In patients suffering from AD, damage to the hippocampal region and impairment of learning and memory is present. It is also known that a buildup of β-amyloid plaques occur in AD patients and that β-amyloid interacts with some subtypes of neuronal nicotinic acetylcholine receptors (neuronal nAChRs). These receptors are composed of five subunits. The most prevalent nAChR subunit composition through the brain as a whole is α7. Previous data produced from our lab suggests that α7 nAChRs are also one of the most prevalent subunits expressed by interneurons within the hippocampal region, a part of the brain known to be involved in memory and learning. It is hypothesized that one mechanism through which learning and memory becomes impaired in AD is through the interaction of β-amyloid with these nAChRs. It has previously been established that nanomolar amounts of β-amyloid inhibit the peak currents of α7 nAChRs. However, concentrations of β-amyloid in the picomolar range, in some studies show an activation of α7 nAChRs, while other studies no activation is seen. In this experiment we show that human α7 subunit nAChRs are not activated by β-amyloid42 at 1 pM- 30 nM concentrations. We also show that short, seven-second applications of β-amyloid interact with the α7 nAChRs to alter the kinetics of the channel, however, the exact mechanism and pattern by which it effects the channel is still unclear.